Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anatole Besarab

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
Current Opinion in Nephrology and Hypertension|October 16, 2004
Vascular access for hemodialysis: 2004 and beyondPrakas T D'Cunha, Anatole Besarab
Advances in Chronic Kidney Disease|February 24, 2009
What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?Anatole Besarab, Stanley Frinak, Jerry Yee
Nephrology News & Issues|April 1, 2008
New developments in anemia management in chronic kidney diseaseRichard Amerling, Anatole Besarab, Cindy Roy
International Journal of Nephrology|December 14, 2011
Surveillance and monitoring of dialysis accessLalathaksha Kumbar, Jariatul Karim, Anatole Besarab
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2002
Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patientsAnatole Besarab, Carolina M Reyes, John Hornberger
The Oncologist|September 19, 2009
Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndromeAnatole Besarab, Walter Hermann Hörl, Donald Silverberg
Vascular Health and Risk Management|April 22, 2010
Managing anemia in patients with chronic heart failure: what do we know?Ankur Sandhu, Sandeep Soman, Michael Hudson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 28, 2004
Effect of differing blood lines on delivered blood flow during hemodialysisJunaid Ahmed, Anatole Besarab, Tom Lubkowski, et al.
The New England Journal of Medicine|January 25, 2008
The normal hematocrit study--follow-upAnatole Besarab, David A Goodkin, Allen R Nissenson, et al.
Advances in Chronic Kidney Disease|February 24, 2009
Hemoglobin variability and hyporesponsiveness: much ado about something or nothing?Jerry Yee, Gerard Zasuwa, Stanley Frinak, et al.
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Current Opinion in Nephrology and Hypertension|October 16, 2004
Vascular access for hemodialysis: 2004 and beyondPrakas T D'Cunha, Anatole Besarab
Advances in Chronic Kidney Disease|February 24, 2009
What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?Anatole Besarab, Stanley Frinak, Jerry Yee
Nephrology News & Issues|April 1, 2008
New developments in anemia management in chronic kidney diseaseRichard Amerling, Anatole Besarab, Cindy Roy
International Journal of Nephrology|December 14, 2011
Surveillance and monitoring of dialysis accessLalathaksha Kumbar, Jariatul Karim, Anatole Besarab
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2002
Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patientsAnatole Besarab, Carolina M Reyes, John Hornberger
The Oncologist|September 19, 2009
Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndromeAnatole Besarab, Walter Hermann Hörl, Donald Silverberg
Vascular Health and Risk Management|April 22, 2010
Managing anemia in patients with chronic heart failure: what do we know?Ankur Sandhu, Sandeep Soman, Michael Hudson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 28, 2004
Effect of differing blood lines on delivered blood flow during hemodialysisJunaid Ahmed, Anatole Besarab, Tom Lubkowski, et al.
The New England Journal of Medicine|January 25, 2008
The normal hematocrit study--follow-upAnatole Besarab, David A Goodkin, Allen R Nissenson, et al.
Advances in Chronic Kidney Disease|February 24, 2009
Hemoglobin variability and hyporesponsiveness: much ado about something or nothing?Jerry Yee, Gerard Zasuwa, Stanley Frinak, et al.
Pageof 9